Project Grant P01CA300738
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $2.7M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Hadley, MA 01035, USA
Similar Awards
- The National Cancer Institute awarded the University of Massachusetts $832,936 under the Cancer Treatment Research program (CFDA 93.395) on June 26, 2026, to develop and evaluate dual-adjuvant, dual-delivery nanoparticle-based cancer vaccines. The research centers on a "prime-pull" vaccination approach that delivers nanoparticles both to lymph nodes for immune priming and to tumors to overcome the immunosuppressive tumor microenvironment. The nanoparticles incorporate two synergistic...
- The National Cancer Institute, a component of the Department of Health and Human Services, awarded the Regents of the University of Michigan $669,278 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop microbial-based cancer therapeutics engineered to deliver localized immune activation while minimizing systemic toxicity. The research focuses on nonpathogenic, tumor-tropic E. coli engineered to display membrane-anchored cytokines, specifically decoy-resistant...
- The National Cancer Institute awarded University of Massachusetts Medical School $1.06 million on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to engineer multi-targeted nanoparticle-based immunotherapy for pancreatic cancer. The funded work develops lipid-based nanoparticles (NPs) carrying RAS pathway inhibitors (trametinib, palbociclib, or RMC-7977) and STING/TLR4 innate immune agonists, designed to home specifically to tumor cells and dendritic cells within the...
- The National Cancer Institute, a division of the National Institutes of Health under the Department of Health and Human Services, awarded $134,000 to the University of Massachusetts Medical School on September 3, 2026, under the Cancer Biology Research program (CFDA 93.396). The recipient will conduct research employing genetically engineered mouse models to elucidate mechanisms by which loss of CAMK2B (calcium/calmodulin-dependent protein kinase II beta) promotes metastasis and immune...
- The National Cancer Institute awarded the University of Massachusetts Medical School $622,611 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and optimize CAS9 nickase as a cancer-selective genotoxic agent targeting focal gene amplification in MYCN-amplified neuroblastoma. The project, titled "Creating Cancer-Specific Genotoxicity by Targeting CAS9 Nickase to Focal Gene Amplifications," addresses an unmet medical need in MYCN-amplified...
- The National Cancer Institute awarded the University of Massachusetts Medical School $167,500 on May 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop and apply a novel sequencing method for mapping 3-methylcytidine (M3C) modifications in messenger RNA at single-nucleotide resolution. The award funds development of HARP-seq, a highly sensitive technique integrating chemical labeling, enrichment strategies, high-throughput sequencing, and bioinformatics to characterize...
- The National Cancer Institute awarded Arizona State University $403,686 under CFDA 93.395 (Cancer Treatment Research) on July 16, 2026, for development of bioengineered networking microbes targeting colon cancer therapy. The project develops genetically modified Salmonella engineered to deliver TRAIL and home to tumor sites, colonizing the tumor microenvironment and initiating localized inflammatory responses that increase tumor immunogenicity. In preclinical mouse models, TRAIL-expressing...
- The National Institutes of Health National Cancer Institute awarded Yale University $432,125 under the Cancer Treatment Research program (CFDA 93.395) on June 1, 2026, to engineer Salmonella-based immunotherapies for solid tumors. The research develops next-generation bacterial cancer therapeutic platforms addressing key barriers in Salmonella-based treatments. The work leverages novel mechanisms of innate immune stimulation to overcome tumor resistance to immune agonists, integrates bacterial...
- Federal Grant Award Summary The Broad Institute of MIT and Harvard received a $443,564 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded on September 2, 2025, with completion by August 31, 2027. The award supports the development of a novel cancer immunotherapy platform utilizing engineered commensal skin bacteria to stimulate tumor-specific T cell immunity. The research focuses on leveraging Staphylococcus epidermidis, a naturally...
- The National Cancer Institute awarded the University of California, San Diego $671,226 on May 15, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop engineered native bacteria—host-derived E. coli strains—as a microbial platform for durable, targeted delivery of therapeutic molecules to the gut to prevent or treat colorectal cancer. The research addresses a critical gap in microbial therapies for colorectal cancer, which the American Cancer Society projects will account...